Eunice André
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eunice André has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
Pierangelo Geppetti
Department of Health Sciences, Clinical Pharmacology and Oncology Unit, University of Florence, Florence, Italy
10 shared publicationsMarcello Trevisani
PharmEste Srl, Ferrara, Italy
9 shared publicationsSerena Materazzi
Department of Health Sciences Clinical Pharmacology Unit University of Florence Florence Italy
9 shared publications- Elaine Cristina Gavioli
Universidade Federal do Rio Grande do Norte
7 shared publications - Joao Batista Calixto
Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil
7 shared publications - Pierangelo Geppetti
Department of Molecular Pathobiology, Pain Research Center, College of Dentistry New York University New York New York USA
7 shared publications
Latest Publications
- Open Access
- 29 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 142-153.e10
miRNA-203b-3p Induces Acute and Chronic Pruritus through 5-HTR2B and TRPV4
- 29 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 142-153.e10
Open AccessmiRNA-203b-3p Induces Acute and Chronic Pruritus through 5-HTR2B and TRPV4
- 1 December 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 912, 174591
Role of nitric oxide, bradykinin B2 receptor, and TRPV1 in the airway alterations caused by simvastatin in rats
- 1 December 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 912, 174591
Role of nitric oxide, bradykinin B2 receptor, and TRPV1 in the airway alterations caused by simvastatin in rats
- Open Access
Topical Application of Cinnamaldehyde Promotes Faster Healing of Skin Wounds Infected with Pseudomonas aeruginosa
Wound healing can be delayed following colonization and infection with the common bacterium Pseudomonas aeruginosa. While multiple therapies are used for their treatment, these are ineffective, expensive, and labour-intensive. Thus, there is an enormous unmet need for the treatment of infected wounds. Cinnamaldehyde, the major component of cinnamon oil, is well known for its antimicrobial properties. Herein, we investigated the effects of sub-inhibitory concentrations of cinnamaldehyde in the virulence of P. aeruginosa. We also assessed its healing potential in P. aeruginosa-infected mouse skin wounds and the mechanisms involved in this response. Sub-inhibitory concentrations of cinnamaldehyde reduced P. aeruginosa metabolic rate and its ability to form biofilm and to cause haemolysis. Daily topical application of cinnamaldehyde on P. aeruginosa-infected skin wounds reduced tissue bacterial load and promoted faster healing. Lower interleukin-17 (IL-17), vascular endothelial growth factor (VEGF) and nitric oxide levels were detected in cinnamaldehyde-treated wound samples. Blockage of transient receptor potential ankyrin 1, the pharmacological target of cinnamaldehyde, abrogated its healing activity and partially reversed the inhibitory actions of this compound on VEGF and IL-17 generation. We suggest that topical application of sub-inhibitory concentrations of cinnamaldehyde may represent an interesting approach to improve the healing of P. aeruginosa-infected skin wounds.
Open AccessTopical Application of Cinnamaldehyde Promotes Faster Healing of Skin Wounds Infected with Pseudomonas aeruginosa
Wound healing can be delayed following colonization and infection with the common bacterium Pseudomonas aeruginosa. While multiple therapies are used for their treatment, these are ineffective, expensive, and labour-intensive. Thus, there is an enormous unmet need for the treatment of infected wounds. Cinnamaldehyde, the major component of cinnamon oil, is well known for its antimicrobial properties. Herein, we investigated the effects of sub-inhibitory concentrations of cinnamaldehyde in the virulence of P. aeruginosa. We also assessed its healing potential in P. aeruginosa-infected mouse skin wounds and the mechanisms involved in this response. Sub-inhibitory concentrations of cinnamaldehyde reduced P. aeruginosa metabolic rate and its ability to form biofilm and to cause haemolysis. Daily topical application of cinnamaldehyde on P. aeruginosa-infected skin wounds reduced tissue bacterial load and promoted faster healing. Lower interleukin-17 (IL-17), vascular endothelial growth factor (VEGF) and nitric oxide levels were detected in cinnamaldehyde-treated wound samples. Blockage of transient receptor potential ankyrin 1, the pharmacological target of cinnamaldehyde, abrogated its healing activity and partially reversed the inhibitory actions of this compound on VEGF and IL-17 generation. We suggest that topical application of sub-inhibitory concentrations of cinnamaldehyde may represent an interesting approach to improve the healing of P. aeruginosa-infected skin wounds.
- 28 July 2017
- Published by Springer Nature in Inflammopharmacology
- Vol. 26 (2) , 521-530
Acid-gastric antisecretory effect of the ethanolic extract from Arctium lappa L. root: role of H+, K+-ATPase, Ca2+ influx and the cholinergic pathway
Arctium lappa L., popularly known as burdock, is a medicinal plant used worldwide. The antiulcer and gastric-acid antisecretory effects of ethanolic extract from roots of Arctium lappa (EET) were already demonstrated. However, the mechanism by which the extract reduces the gastric acid secretion remains unclear. Therefore, this study was designed to evaluate the antisecretory mode of action of EET.
- 28 July 2017
- Published by Springer Nature in Inflammopharmacology
- Vol. 26 (2) , 521-530
Acid-gastric antisecretory effect of the ethanolic extract from Arctium lappa L. root: role of H+, K+-ATPase, Ca2+ influx and the cholinergic pathway
Arctium lappa L., popularly known as burdock, is a medicinal plant used worldwide. The antiulcer and gastric-acid antisecretory effects of ethanolic extract from roots of Arctium lappa (EET) were already demonstrated. However, the mechanism by which the extract reduces the gastric acid secretion remains unclear. Therefore, this study was designed to evaluate the antisecretory mode of action of EET.
- 1 December 2016
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 41, 25-33
Involvement of the TRPV1 receptor in plasma extravasation in airways of rats treated with an angiotensin-converting enzyme inhibitor
- 1 December 2016
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 41, 25-33
Involvement of the TRPV1 receptor in plasma extravasation in airways of rats treated with an angiotensin-converting enzyme inhibitor
- 10 July 2016
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 30 (10) , 1062-1068
Short term, low dose fluoxetine blocks estrous cycle-linked changes in responsiveness to diazepam in female rats
Anxiety behavior in female Wistar rats was assessed at different stages of the estrous cycle using the elevated plus maze (EPM). No differences were observed at any cycle stage. Pretreatment with diazepam (1 mg kg−1intraperitoneal (i.p.)) 30 min before testing produced an anxiolytic effect (significant increase in percentage of time in the open arms compared to control group in the same cycle phase) in animals in proestrus, estrus, and early diestrus but had no effect in rats in late diestrus. Locomotor activity (total arm entries) was unchanged at any cycle phase. When rats in the late diestrus phase were pretreated with the selective serotonin reuptake inhibitor fluoxetine (1.75 mg kg−1i.p. on the afternoon of early diestrus and again in the morning of late diestrus) diazepam produced an anxiolytic effect (increase percentage time in the open arms). This dose is sufficient to raise brain allopregnanolone concentration without affecting 5-hydroxytryptamine (5-HT) systems. We propose that insensitivity to diazepam in late diestrus is due to increased expression of benzodiazepine insensitive α4 subunit-containing gamma-aminobutyric acid A (GABAA)receptors triggered by a sharp decrease in brain allopregnanolone concentration. Pretreatment with fluoxetine to raise brain allopregnanolone concentration during late diestrus prevents the withdrawal effect.
- 10 July 2016
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 30 (10) , 1062-1068
Short term, low dose fluoxetine blocks estrous cycle-linked changes in responsiveness to diazepam in female rats
Anxiety behavior in female Wistar rats was assessed at different stages of the estrous cycle using the elevated plus maze (EPM). No differences were observed at any cycle stage. Pretreatment with diazepam (1 mg kg−1intraperitoneal (i.p.)) 30 min before testing produced an anxiolytic effect (significant increase in percentage of time in the open arms compared to control group in the same cycle phase) in animals in proestrus, estrus, and early diestrus but had no effect in rats in late diestrus. Locomotor activity (total arm entries) was unchanged at any cycle phase. When rats in the late diestrus phase were pretreated with the selective serotonin reuptake inhibitor fluoxetine (1.75 mg kg−1i.p. on the afternoon of early diestrus and again in the morning of late diestrus) diazepam produced an anxiolytic effect (increase percentage time in the open arms). This dose is sufficient to raise brain allopregnanolone concentration without affecting 5-hydroxytryptamine (5-HT) systems. We propose that insensitivity to diazepam in late diestrus is due to increased expression of benzodiazepine insensitive α4 subunit-containing gamma-aminobutyric acid A (GABAA)receptors triggered by a sharp decrease in brain allopregnanolone concentration. Pretreatment with fluoxetine to raise brain allopregnanolone concentration during late diestrus prevents the withdrawal effect.
- 1 May 2015
- Published by Elsevier in Behavioural Brain Research
- Vol. 284, 187-195
There is more to the picture than meets the rat: A study on rodent geometric shape and proportion preferences
- 1 May 2015
- Published by Elsevier in Behavioural Brain Research
- Vol. 284, 187-195
There is more to the picture than meets the rat: A study on rodent geometric shape and proportion preferences
- 1 January 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 747, 105-113
The involvement of the TRPA1 receptor in a mouse model of sympathetically maintained neuropathic pain
- 1 January 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 747, 105-113
The involvement of the TRPA1 receptor in a mouse model of sympathetically maintained neuropathic pain
- 1 January 2015
- Published by Elsevier in Life Sciences
- Vol. 120, 8-12
Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test
- 1 January 2015
- Published by Elsevier in Life Sciences
- Vol. 120, 8-12
Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test
- 28 August 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (18) , 4289-4299
The blockade of transient receptor potential ankirin 1 (TRPA1) signalling mediates antidepressant‐ and anxiolytic‐like actions in mice
Background and Purpose: Transient receptor potential vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1) are involved in many biological processes, including nociception and hyperalgesia. Whereas the involvement of TRPV1 in psychiatric disorders such as anxiety and depression has been reported, little is known regarding the role of TRPA1 in these conditions.Experimental Approach: We investigated the role of TRPA1 in mice models of depression [forced swimming test (FST)] and anxiety [elevated plus maze (EPM) test].Key Results: Administration of the TRPA1 antagonist (HC030031, 30 nmol in 2 μL, i.c.v.) reduced immobility time in the FST. Similar results were obtained after oral administration of HC030031 (30–300 mg·kg−1). The reduction in immobility time in FST induced by HC030031 (100 mg·kg−1) was completely prevented by pretreatment with TRPA1 agonist, cinnamaldehyde (50 mg·kg−1, p.o.), which per se was inactive. In the EPM test, pretreatment with cinnamaldehyde (50 mg·kg−1, p.o.), which per se did not affect behaviour response, prevented the anxiolytic‐like effect (increased open arm exploration) evoked by TRPA1 blockade (HC030031, 100 mg·kg−1, p.o.). Treatment with either cinnamaldehyde or HC030031 did not affect spontaneous ambulation. Furthermore, TRPA1‐deficient mice showed anxiolytic‐ and antidepressant‐like phenotypes in the FST and EPM test respectively.Conclusion and Implications: The present findings indicate that genetic deletion or pharmacological blockade of TRPA1 produces inhibitory activity in mouse models of anxiety and depression. These results imply that TRPA1 exerts tonic control, promoting anxiety and depression, and that TRPA1 antagonism has potential as an innovative strategy for the treatment of anxiety and mood disorders.
- 28 August 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (18) , 4289-4299
The blockade of transient receptor potential ankirin 1 (TRPA1) signalling mediates antidepressant‐ and anxiolytic‐like actions in mice
Background and Purpose: Transient receptor potential vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1) are involved in many biological processes, including nociception and hyperalgesia. Whereas the involvement of TRPV1 in psychiatric disorders such as anxiety and depression has been reported, little is known regarding the role of TRPA1 in these conditions.Experimental Approach: We investigated the role of TRPA1 in mice models of depression [forced swimming test (FST)] and anxiety [elevated plus maze (EPM) test].Key Results: Administration of the TRPA1 antagonist (HC030031, 30 nmol in 2 μL, i.c.v.) reduced immobility time in the FST. Similar results were obtained after oral administration of HC030031 (30–300 mg·kg−1). The reduction in immobility time in FST induced by HC030031 (100 mg·kg−1) was completely prevented by pretreatment with TRPA1 agonist, cinnamaldehyde (50 mg·kg−1, p.o.), which per se was inactive. In the EPM test, pretreatment with cinnamaldehyde (50 mg·kg−1, p.o.), which per se did not affect behaviour response, prevented the anxiolytic‐like effect (increased open arm exploration) evoked by TRPA1 blockade (HC030031, 100 mg·kg−1, p.o.). Treatment with either cinnamaldehyde or HC030031 did not affect spontaneous ambulation. Furthermore, TRPA1‐deficient mice showed anxiolytic‐ and antidepressant‐like phenotypes in the FST and EPM test respectively.Conclusion and Implications: The present findings indicate that genetic deletion or pharmacological blockade of TRPA1 produces inhibitory activity in mouse models of anxiety and depression. These results imply that TRPA1 exerts tonic control, promoting anxiety and depression, and that TRPA1 antagonism has potential as an innovative strategy for the treatment of anxiety and mood disorders.